Quick Answer
Cocrystal Pharma, Inc. reported Research And Development Expense of $5.06 million for the year ending 2025.
- Cocrystal Pharma, Inc. showed a decrease of -59.7% in Research And Development Expense from 2024 to 2025.
- This data is from Cocrystal Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Cocrystal Pharma, Inc.'s Research And Development Expense has grown by 1,998.6%.
- Historical annual values: Fiscal year 2025: $5.06 million | Fiscal year 2024: $12.54 million | Fiscal year 2023: $15.17 million | Fiscal year 2022: $12.39 million | Fiscal year 2021: $8.79 million | Fiscal year 2020: $6.03 million | Fiscal year 2019: $4.00 million | Fiscal year 2018: $4.67 million | Fiscal year 2017: $5.82 million | Fiscal year 2016: $101.68 million | Fiscal year 2015: $47.26 million | Fiscal year 2014: $4.07 million | Fiscal year 2013: $3.86 million | Fiscal year 2012: $489.3 thousand | Fiscal year 2011: $423.2 thousand | Fiscal year 2010: $240.9 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: